Charu Aggarwal, MD, MPH, FASCO

So honored to have been interviewed! Thank you @jamecancerdoc @ASCOPost and looking forward to #ASCO25 @ASCO @OncoAlert @IMG_Oncologists @HemOncWomenDocs @IASLC @PennCancer @PennMDForum

FLAURA2 press release: addition of chemotherapy to 1L osimertinib in #EGFR NSCLC improves overall survival. Already approved based on significant PFS benefit. Awaiting data to see degree of OS benefit to consider vs MARIPOSA. Important positive update! astrazeneca.com/media-centre/p…

FDA grants accelerated approval for datopotamab deruxtecan, anti-TROP2 ADC, for #EGFR mutant NSCLC after prior TKI and chemotherapy. An active agent, based on TROPION-Lung01 and 05. Important toxicities include stomatitis and ocular effects. ascopost.com/news/june-2025…

New @US_FDA accelerated approval: Dato-DXd for EGFR+ NSCLC after prior EGFR therapy + platinum chemo. ▫️n=114, TROPIONLung01&05 ▫️ORR: 45% ▫️DoR: 6.5 mo ⚠️ ILD, ocular AEs, stomatitis, embryo-fetal risk @OncoAlert #lcsm

On June 23, 2025, the FDA granted accelerated approval to datopotamab deruxtecan-dlnk for adults with locally advanced or metastatic EGFR-mutated non-small cell #LungCancer ( #NSCLC ) who have previously received EGFR-directed therapy and platinum-based chemotherapy.…

FDA approves taletrectinib for #ROS1 NSCLC based on TRUST I and TRUST II trials showing 1L RR 85-90% with 63-72% of responses lasting ≥12 months and post TKI, RR 52-62%. Taletrectinib has selectivity over TrkB so should have less neurotoxicity. fda.gov/drugs/resource…

In this episode of the @IASLC podcast, Lung Cancer Considered, I am joined by Drs. @NarjustFlorezMD @CharuAggarwalMD @FordePatrick to discuss the most impactful lung cancer studies from #ASCO25. Available wherever you download podcasts! iaslc.org/iaslc-news/lun…

#RapidUpdates from #ASCO25! This is a must listen quick update in #LungCancer w/ @StephenVLiu @NarjustFlorezMD @FordePatrick @IASLC @ASCO @PennCancer

~13yrs of neoadjuvant adventure comes to positive conclusion (for now)! In @NEJM today & presented at #ASCO25 5 yr survival for pts w lung cancer that can be removed by surgery is better with just 3 doses of immunotherapy before the operation! nejm.org/doi/full/10.10… #LCSM 1/

🚨If you were not at #ASCO25 for ASCO Highlights today, you must stream @lungoncdoc excellent presentation! Very informative!

Thoughtful discussion in our #ASCO25 session on perioperative approaches in #NSCLC, including rare drivers and hard-to-treat genotypes— alongside stellar faculty @CharuAggarwalMD & @kaushalpar. @ASCO @DanaFarberNews @NarjustFlorezMD @OncoAlert @MarceloCorassa @DanaFarber

Time to Back to the ward. With more knowledge. More energy. More courage. Thank you #ASCO25 for 5 unforgettable days—full of learning, connection, and hope. See you soon 💙 @ASCO @OncoAlert #oncology #cancer @DrChoueiri @yekeduz_emre @DanaFarber @CParkMD @neerajaiims…

Great talk by the amazing @CharuAggarwalMD about definition of curative therapy in patients with "common" AGAs, in other words, EGFR/ALK. We are still trying to understand exactly TKIs are going to fit in patients candidates to surgery. #ASCO25

This is going to be a great session with @CharuAggarwalMD @kaushalpar!! Biomarker testing absolutely matters even in early-stage disease for patients with NSCLC! #ASCO25 @ASCO

#ASCO25 @ASCO has been incredible - breadth and depth of research presented by @PC3Innovation @PennCancer @PennMedicine @PennMDForum Here is a quick recap! tinyurl.com/49yvc65f #LCSM #QoL #AI #FinancialToxicity @Ron_cology @lynn_schuchter @MMarmarelis

Last day of #ASCO25!! If you’re still in Chicago this morning, please join us for the highlights of the day session!! 📍Hall D1 @ASCO @MDAndersonNews

🚨 Don’t miss our educational session today! 📍 E450A, 8 AM CT 🎤 @kaushalpar @BRicciutiMD @ASCO #ASCO25 @OncoAlert #LCSM

🔍 Genomics meets the OR in #NSCLC at #ASCO25! Explore how EGFR, ALK, KRAS, RET & more shape perioperative strategies & surgical planning. Precision medicine is rewriting the playbook for early-stage lung cancer @CharuAggarwalMD @kaushalpar

🚨 Don’t miss our educational session today! 📍 E450A, 8 AM CT 🎤 @kaushalpar @BRicciutiMD @ASCO #ASCO25 @OncoAlert #LCSM

Was so good to see you! Hope to see you soon, congrats on a terrific meeting! @ASCO #ASCO25 @AmandaBinDC @sarah_c_hopkins

#ASCO25 Dr. @charlesrudin presents interim analysis of DeLLphi-304: randomized phase II study of tarlatamab (DLL3 TCE) vs 2L chemo in #SCLC. Chemo was mostly topotecan; 45% of pts were platinum resistant. Clear OS benefit with HR 0.60 (13.6m vs 8.3m). PFS 4.2 vs 3.7m, HR 0.71.